74results about "Electrophoretic profiling" patented technology

The present invention provides systems and processes for the collection and identification of macromolecules, such as biologically-derived macromolecules (e.g., proteins and nucleic acids), by measuring and comparing the molecular weight signatures of macromolecular samples. Reproducible molecular weight signatures provides reliable sample identification. In the case of viruses, proteomic molecular weight signatures can be used for identifying viral agents.

The present invention is a method for determining protein expression profiles in disease or an altered biological state. The method is based on the use of two-dimensional (2D) gel electrophoresis where the gel images are assigned two different colors. The gels are then compared by an overlay procedure that allows for identification and quantification of unique proteins by determining which colors are detected in the superimposed images and the density of those colors.

Electrophoresis Compositions, methods and kits useful for, among other things, detecting, quantifying and/or characterizing analytes are provided. The compositions are useful as electrophoresis standards for determine the isoelectric point and molecular weight of an analyte. The electrophoresis standards generally comprise at least one label moiety and one or more reactive moieties that when activated attach the standard to a substrate.

Electrophoretic separation methods and systems for performing the same are provided. The methods and systems find use in a variety of different electrophoretic separation applications, such as sub-cellular Western blotting of single cells.

Microfluidic devices and methods for using the same are provided. Aspects of the invention include microfluidic devices that include a separation medium and a pan-capture binding medium. The microfluidic devices are configured to subject a sample to two or more directionally distinct electric fields. Also provided are methods of using the devices as well as systems and kits that include the devices. The devices, systems and methods find use in a variety of different applications, including diagnostic and validation assays.

The invention discloses a method and a device for detecting the carcinoembryonic antigen content. The method comprises the following steps of (1) uniformly mixing a fluorescent substance with a connection agent to obtain a first mixture, and then mixing the first mixture with a carcinoembryonic antigen aptamer solution; (2) uniformly mixing a mixed solution with a graphene oxide solution to cause fluorescence quenching so as to obtain a carcinoembryonic antigen aptamer-phosphor/graphene oxide solution; (3) uniformly mixing a sample to be detected and the carcinoembryonic antigen aptamer-phosphor/graphene oxide solution to cause fluorescence recovery; and (4) performing capillary electrophoresis, performing fluorescent detection at a position meeting the requirement that the distance from the position to a positive electrode is 1/2-2/3 of the total length of a capillary, and measuring the concentration of a carcinoembryonic antigen. The device comprises a capillary electrophoresis device and a fluorescence inspection device, wherein the total length of the capillary of the capillary electrophoresis device is 50-100cm, and the inner diameter is 50-100 microns; a detection window is arranged in a position meeting the requirement that the distance from the position to a positive electrode buffering solution tank is 1/2-2/3 of the total length of the capillary; the fluorescence inspection device is arranged at the capillary detection window. The method and the device are high in sensitivity, low in detection limit and high in detection efficiency and can be applied to early screening of cancers.

A method for screening wheat varieties with low celiac sprue toxicity based on T cell epitopes comprises the following steps: separating and extracting wheat gluten protein in two steps, performing SDS-PAGE electrophoresis combined with PageBlue TM staining method to identify the gluten protein, detecting celiac sprue T cell epitopes caused by the gluten protein through immunoblotting and other steps. According to the invention, T cell epitopes-based screening method is adopted to screen out the wheat varieties with low celiac sprue toxicity, so that safe and reliable low gluten food can be supplied for celiac sprue patients from the origin of raw materials, and the safety risk of the celiac sprue patients is reduced.

A method for diagnosing obstructive sleep apnea in a patient comprises identifying at least one protein biomarker for obstructive sleep apnea; obtaining a sample from the patient; and testing the sample for presence of the at least one protein biomarker. The protein biomarkers may include alpha-1 B-glycoprotein; kallikrein, laminin, aldosterone-binding protein and/or urocortin-2 precursor. The presence of the protein biomarkers may be detected using antibodies. These antibodies may be provided in an array for detecting the presence of the at least one protein biomarker or a pattern of protein biomarkers.

Disclosed are methods and apparatus for separation of biomolecules via two-dimensional gel electrophoresis, methods and apparatus for immunoblotting separated biomolecules, and methods for the use of biomolecules processed via the methods and apparatus of the present invention, including use in a clinical setting. The methods and apparatus for separation of biomolecules via two-dimensional gel comprises vertical agarose gel electrophoresis in the first dimension, and the electrophoresis of a novel non-denaturing 3-35% concave gradient polyacrylamide gel in the second dimension. This novel gel can be cast in a modified gel caster that can facilitate the pouring of multiple gels simultaneously. The methods and apparatus for immunblotting are useful with any type of immunoblotting, including Western blot, Northern blot, and Southern blot analyses. These methods and apparatus provide safe, efficient and cost-effective immunoblots, while facilitating the reduction of exposure to toxic or radioactive materials, as well as the disposal of those materials.

The invention discloses a method for detecting fish parvalbumin by capillary electrophoresis. The method comprises the following steps: (1) extracting holoprotein from fish-muscle and dissolving in an equilibrium buffer with pH being 7-8, loading into an anion exchange chromatographic column, eluting with an eluant and collecting a solution corresponding to a flow-through peak so as to obtain a sample; and (2) carrying out capillary zone electrophoresis on the sample to obtain substituting peak area obtained in electrophoretogram into a standard curve regression equation of fish parvalbumin and calculating to obtain concentration of fish parvalbumin in the sample solution. The method of the invention is a method for rapid, qualitative and quantitative detection of aquatic product allergen fish parvalbumin by capillary electrophoresis. The method for qualitative and quantitative analysis of fish parvalbumin has been reported in the literature, and provides new basis for rapid and accurate detection of fish parvalbumin.

The present invention relates to, among other things, a gel electrophoresis system for detecting the level of specific Apolipoproteins and/or lipoprotein particles present in intact lipid particles in a biological sample. The system includes a gel substrate to receive a biological sample, at least two lipoprotein-binding complexes. Each complex includes an antibody that binds a lipoprotein particle or a portion thereof, which is bound to a signal producing molecule capable of producing or causing production of a detectable signal. The system also includes a device for detecting the detectable signal. The present invention also relates to methods of assessing the level of specific Apolipoproteins and/or lipoprotein particles present in a biological sample, determining whether a subject is at increased risk for cardiovascular disease, and monitoring the risk for developing cardiovascular disease.

The invention belongs to the technical field of crops breeding, and mainly relates to a breeding method of red-grain early-ripe strong-gluten high-quality wheat. The breeding method comprises the following steps: performing primary hybridization by adopting French wheat variety NSA00-0061 as a female parent and LUYUAN202 as a male parent to obtain hybrid seeds; performing secondary hybridization by adopting the hybrid seeds as the female parent and Jimai 22 as the male parent to obtain generation-F1 seeds; and planting and breeding for the generation-F1 seeds. Since the ripe period of NSA00-0061 is 15 days later than the domestic varieties, the filial generation obtained by virtue of the hybridization of NSA00-0061 and Luyuan202 is still late-maturing; and by virtue of the secondary hybridization, the male parent of the secondary hybridization is Jimai 22, so that the mature period of the obtained generation-F1 seeds is shortened to be consistent with the mature period of the domestic wheat varieties. According to the breeding method, subunit 5+10 in the foreign seed varieties is introduced into a domestic material, and the foreign wheat subunit and the domestic wheat variety subunit are successively polymerized, and the polymerization of various subunits enables the wheat variety to have a high quality of strong gluten.

The invention relates to the technical field of enzyme linked immune, and discloses a composition for an enzyme linked immunosorbent assay kit, an anti-nuclear antibody spectrum detection kit and a preparation method thereof. The composition comprises sealing liquid and ELISA diluents; the sealing liquid contains casein, saccharose, PBS, mannitol, Tween20, lycine and sodium azide; the ELISA diluents contain PBS, casein, sodium p-hydroxybenzoate, PEG, lycine and Proclin300. By starting from the sealing liquid and the ELISA diluents of the enzyme linked immunosorbent assay kit, the proper ingredients are selected, so that the enzyme linked immunosorbent assay kit can maintain the detection stability for a long time. Meanwhile, the anti-nuclear antibody spectrum detection kit prepared from the composition has higher stability; the guarantee period is 2 years or more.

The invention discloses a magnetic field assisted dielectrophoresis enrichment method for nanoparticle labeled immunodetection. By utilizing a nanoparticle labeled antibody or antigen, a method for screening and enriching aggregate formed by performing immunoconjugate on a magnetic nanoparticle and sensing nanoparticle labeled antibody or antigen by using magnetic field assisted dielectrophoresis is designed. An alternating electric field is applied between parallel non-uniform electrodes, spatial directional movement of nanoscale particles in the solution is realized, selective enrichment of nanoparticle and magnetic nanoparticle immunoreaction aggregate in a micro area on the surface of a transparent electrode in a complex solution is realized in a specific voltage magnitude and frequency and magnetic field intensity range, and the method is used for sensitivity immunodetection.

A method of counting protein subunits to determine the oligomeric state of an oligomeric protein complex includes tagging and expressing the protein subunits with a mass/charge tag and selectively removing each mass/charge tag. The number of protein subunits of the oligomeric complex corresponds to the number of mass/charge tags removed.

The present invention relates to a novel combination of methods that enables identification of proteins secreted from intracellular bacteria regardless of the secretion pathway. The invention further provides proteins that are identified by these methods. Secreted proteins are known to be suitable candidates for inclusion in immunogenic compositions and/or diagnostic purposes. The invention also provides peptide epitopes (T-cell epitopes) from the identified secreted proteins, as well as nucleic acid compounds that encode the proteins. The invention further comprises various applications of the proteins or fragments thereof, such as pharmaceutical and diagnostic applications.

The instant disclosure describes an electrophoretic procedure capable of resolving and isolating ultra high molecular weight (MW) protein aggregates from nerve tissue. The procedure is based on the use of composite agarose-polyacrylamide gel electrophoresis (CAPAGE) and resolves proteins and protein aggregates over the range of from approximately 225 kDa to approximately 30,000 kDa. Triton X-100 precipitation is used to obtain a cytoskeleton protein fraction that is subsequently resuspended and subjected to gel electrophoresis. This method demonstrates that a protein aggregate of approximately 30,000 kDa is characteristic of normal murine spinal cord tissue and that the amount of said protein aggregate is increased in spinal cord homogenate obtained from transgenic mice bearing copies of a mutant human gene characteristic of familial amyotrophic lateral sclerosis. This method for separating nerve tissue ultra high MW cytoskeleton protein aggregates can prove useful in a variety of future biophysical and pharmacological studies related to the etiologies of Charcot-Marie-Tooth disease, Alzheimer's disease, Parkinson's disease, diseases based on expansions in tandem DNA repeats, spinal muscular atrophy, Friedreich's ataxia, giant axon neuropathy, juvenile ceroid-lipofuscinosis, amyotrophic lateral sclerosis, diabetic polyneuropathy and Down's syndrome.

The present invention provides methods for identifying candidate biomarkers in the plasma microparticle proteome. It also provides methods for isolating, identifying, and analyzing microparticles derived from plasma, particularly platelet-poor plasma.

The present invention relates to an efficient mAb panel-based expression profiling technology platform suitable for global and accurate measurement of proteins, peptides and metabolites in complex mixtures. The platform is comprised of new and well established technologies that are coupled in a unique fashion to provide a novel platform technology for (i) the discovery of differentially displayed elements of complex protein, peptide and metabolite mixtures and (ii) the development of robust mAb based assays that detect the differentially expressed elements.